Study of nicotinamide riboside for Huntington's disease
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic test showing you carry the Huntington's disease gene (36 or more CAG repeats).
- You must have clear symptoms of Huntington's disease, diagnosed by a doctor, and be in early or mid-stage disease.
- You must be able to walk indoors with or without a walking aid.
- You must be able to do pen-and-paper tests and answer questionnaires.
- You must not have taken vitamin B3 supplements in the last 3 months.
- You must not have had gene therapy for Huntington's disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
This Phase 2 study tests whether taking thiamine and biotin together can improve symptoms in people with Huntington’s disease. It looks especially at people with confirmed genetic Huntington’s disease and certain types of movement and/or mood symptoms.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
This study tests whether a medication called pridopidine can help slow the progression of Huntington's disease symptoms in adults. Huntington's is a genetic disorder affecting movement, mood, and thinking, and this trial aims to see if pridopidine improves daily functioning and quality of life.
This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.
This is an early-phase study testing a new drug (RG6496) for people with Huntington's disease. The study will check the drug's safety and how the body processes it, and it requires two doses given about 6 months apart.
Hear when a new Huntington Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.